October 3rd 2025
Alto Neuroscience's ALTO-101 gains FDA Fast Track designation, promising a novel treatment for cognitive impairment in schizophrenia.
Research That Can Change Clinical Practice in Psychotic Disorders
July 28th 2015The need to stay up-to-date with the most current evidence-based information is becoming harder than ever. For this reason, the authors identify and evaluate published research that may have a direct bearing on clinical practice.
Read More
Large Trials for First-Episode Psychosis: One Debuts, Another Marks 10 Years
May 19th 2015Progress in identifying and effectively treating first-episode schizophrenia was marked by the simultaneous publication of a report on a 6-year study and on the 10-year follow-up of a large-scale trial.
Read More